Last reviewed · How we verify
Mucopolysaccharidosis, MPS-VII — Treatment Landscape & Competitive Intelligence
3 marketed
0 Phase 3
0 Phase 2
Live · 30-min refresh
Marketed treatment landscape
| Drug | Generic | Sponsor | Class | Target | Line of therapy | First approval |
|---|---|---|---|---|---|---|
| Mepsevii | VESTRONIDASE ALFA | Ultragenyx Pharm Inc | Lysosomal beta Glucuronidase [EPC] | 2017-01-01 | ||
| MEPSEVII | VESTRONIDASE ALFA-VJBK | ULTRAGENYX PHARM INC | ||||
| Mepsevii | Mepsevii | Ultragenyx Pharmaceutical Inc |
Phase 3 pipeline
Phase 2 pipeline
Recent regulatory actions (last 90 days)
Upcoming PDUFA dates (next 180 days)
Sponsor landscape
- ULTRAGENYX PHARM INC · 1 drug in Mucopolysaccharidosis, MPS-VII
- Ultragenyx Pharm Inc · 1 drug in Mucopolysaccharidosis, MPS-VII
- Ultragenyx Pharmaceutical Inc · 1 drug in Mucopolysaccharidosis, MPS-VII
Subscribe to ongoing alerts
Every new regulatory action, PDUFA date, or trial completion in Mucopolysaccharidosis, MPS-VII:
- Mucopolysaccharidosis, MPS-VII treatment updates — RSS
- Mucopolysaccharidosis, MPS-VII treatment updates — Atom
- Mucopolysaccharidosis, MPS-VII treatment updates — JSON
Cite this brief
Drug Landscape (2026). Mucopolysaccharidosis, MPS-VII — Treatment Landscape & Competitive Intelligence Brief. https://druglandscape.com/ci/disease/mucopolysaccharidosis-mps-vii. Accessed 2026-06-10.
Related
- Mucopolysaccharidosis, MPS-VII full disease profile — treatment pathway, diagnostics, guidelines
- Browse all CI briefs
- Build a custom feed
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing